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We present methods for imputing data for ungenotyped markers and for inferring haplotype phase in large data sets of unrelated indi-
viduals and parent-offspring trios. Our methods make use of known haplotype phase when it is available, and our methods are compu-
tationally efﬁcient so that the full information in large reference panels with thousands of individuals is utilized. We demonstrate that
substantial gains in imputation accuracy accrue with increasingly large reference panel sizes, particularly when imputing low-frequency
variants, and that unphased reference panels can provide highly accurate genotype imputation. We place our methodology in a uniﬁed
framework that enables the simultaneous use of unphased and phased data from trios and unrelated individuals in a single analysis. For
unrelated individuals, our imputation methods produce well-calibrated posterior genotype probabilities and highly accurate allele-
frequency estimates. For trios, our haplotype-inferencemethod is four orders ofmagnitude faster than the gold-standard PHASE program
and has excellent accuracy. Our methods enable genotype imputation to be performedwith unphased trio or unrelated reference panels,
thus accounting for haplotype-phase uncertainty in the reference panel. We present a useful measure of imputation accuracy, allelic R2,
and show that this measure can be estimated accurately from posterior genotype probabilities. Our methods are implemented in version
3.0 of the BEAGLE software package.Introduction
Genotype imputation and haplotype-phase inference are
important approaches for improving the power of genome-
wide association (GWA) studies.1 Imputation has resulted
in the detection of additional associations, particularly
when combining data from multiple studies genotyped
on different platforms.2–5 Haplotype-based association
testing with phased haplotype data can also detect addi-
tional associations.6 Imputation can be used for identifying
association between known, ungenotyped genetic variants
and a trait. In contrast, haplotype-based association testing
is not limited to testing known genetic variants, but the
interpretation of haplotype-based association analysis is
typically more difﬁcult.
Imputation can be used for inferring genotypes at
markers that have not been genotyped in one’s sample.
This is possible by using patterns of haplotypic variation
seen in another data set (the reference panel) that includes
the larger set of markers. There are a variety of existing
methods for imputation or testing of ungenotyped
markers.7–12 Until now, the reference panels used for impu-
tationhave been small, whichhas limited imputation accu-
racy.However,much larger reference panels are now, orwill
soon be, available for many populations because of large-
scale sequencing and genotyping projects (e.g., HapMap
phase 3 and the 1000 genomes project; seeWeb Resources).
We show that larger reference panels substantially increase
imputation accuracy, particularly for low-frequency vari-
ants. Our previous work has shown that the performance
of the haplotype-frequency models that support imputa-
tion can depend on reference panel size.13 Methods that210 The American Journal of Human Genetics 84, 210–223, Februarperform exceptionally well for small data sets may have
suboptimal performance for large data sets, particularly
when computational constraints limit the complexity of
the haplotype-frequency model. Existing imputation
methods have been tested and used with small reference
panels of 60 phased individuals. New imputation methods
are needed that can accommodate large reference panels
and combinations of unrelated and parent-offspring data.
We present newmethods for imputation of ungenotyped
markers in which the sample and reference panel contain
data for parent-offspring trios, parent-offspring pairs, and
unrelated individuals. Our methods use a haplotype-
frequency model that is computationally efﬁcient and
that canmake full use of the information in large reference
panels.13 We have implemented our methods in a software
package, BEAGLE. We show that BEAGLE scales easily to
large reference panels with thousands of individuals,
whereas IMPUTE,7 one of the best-performing methods
for reference panels with 60 phased individuals from the
HapMap,14 does not scale well to larger reference panels.
Our currentwork also extends our haplotype-phase-infer-
ence methods for unrelated individuals to large trio data
sets. Trios contain additional information on haplotype
phase compared to unrelated individuals, in the form of
constraints imposed by the rules of Mendelian inheritance.
Thus,using speciﬁc trio-phasingmethods leads toextremely
accurate estimates of haplotype phase.15 Our trio-phasing
method is four orders of magnitude faster than the gold-
standard PHASE program and has excellent accuracy.
We also present extensive results of data analyses, inves-
tigating not only the performance of ourmethodology, but
also examining questions of wider interest. In particular,1Department of Statistics, University of Auckland, Auckland 1142, New Zealand
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we demonstrate the power advantages of large reference
panels for association testing, even when the reference
panels are unphased.
Researchers must be able to assess the accuracy of
imputed genotypes when the true genotype is unknown,
so that poorly imputed markers can be identiﬁed prior to
downstream analysis. To this end, we introduce a measure
of imputation accuracy, allelic R2, the squared correlation
between the allele dosage with the highest posterior prob-
ability and the true allele dosage. We discuss the advan-
tages of the allelic R2 measure, and we show that it can
be estimated from the posterior genotype probabilities
(see Appendix 1).
Material and Methods
Hidden Markov Model
We present a uniﬁed framework for inferring haplotype phase and
missing data that is applicable to a general class of hidden Markov
models (HMMs), which we call haplotype HMMs (see Appendix 2
and Rabiner16). In Appendix 2, we show that haplotype HMMs
can be generalized in an obvious way for producing HMMs for
genotype data for individuals, parent-offspring pairs (one parent
and one child), and parent-offspring trios (two parents and one
child). Analysis of haplotype HMMs can be used for inferring
haplotypes and imputing missing genotypes for individuals,
parent-offspring pairs, and parent-offspring trios conditional
upon the observed genotype data. For example, with parent-
offspring trios, the haplotype HMMprovides amodel of haplotype
frequencies for the four independent haplotypes in a parent-
offspring trio. The four independent haplotypes are the trans-
mitted and untransmitted haplotypes from each parent, and
each set of four haplotypes corresponds to a possible trio phasing.
The observed genotype data for a trio constrain the possible trio
phasings for each trio. These constraints are incorporated in the
emission probabilities for the HMM.
In Appendix 3, we present ourmethods for building a haplotype
HMM from phased genotype data. Haplotypes from any combina-
tion of individual or parent-offspring trios (with or without an
ungenotyped parent) can be used for building the model, if haplo-
types shared by parent and child are counted as a single haplotype.
Individuals, parent-offspring pairs, and parent-offspring trios
contribute two, three, and four independent haplotypes, respec-
tively. We use an iterative algorithm for ﬁtting a haplotype HMM
to genotype data that alternates between model building and
sampling. In the model-building step, current estimates of phased
haplotypes are used for building a new haplotype HMM. In the
sampling step, new haplotypes are sampled for each individual,
parent-offspring pair, or parent-offspring trio conditional upon
the genotype data and the current haplotype HMM. The iterative
algorithm begins with model building. Estimated phased haplo-
types for the initial iteration are obtained by imputing missing
genotypes at random according to allele frequencies and randomly
phasing heterozygous genotypes. With our methods, typically ten
iterationsof themodel-buildingandsampling steps are sufﬁcient to
obtain a very accurate haplotype HMM.
We found that we were able to greatly improve the performance
of ourmethod by including haplotypeweights and adjusting these
weights during the ﬁrst few iterations of the algorithm. Eachhaplo-
type is assigned a unit weightwhen building themodelwhen thereThe Americis sporadic missing data (see Appendix 3). When imputing ungen-
otyped markers in a sample with a reference panel, we assign
reference panel haplotypes a weight of 1, and we down-weight
the haplotypes in the sample during the model-building phase
for the ﬁrst ﬁve iterations of the algorithm. If there areNhaplotypes
in the sample, we assign eachhaplotype aweight of 1/N for the ﬁrst
two iterations and aweight of 1/N(6-k)/4 for iterations k¼3, 4, and5.
For iterationsR6, all haplotypes in the sample and reference panel
are assigned weight of 1. This weighting scheme forces the initial
estimates of haplotype phase and missing data in the sample to
be primarily determined by the reference panel data. Our experi-
ments with simulated data indicate that if down-weights are not
used, hundreds of iterations are required to achieve the imputation
accuracy obtained when using down-weights with ten iterations
(data not shown).
Our methods also permit one to sample multiple haplotypes for
each individual, parent-offspring pair, and parent-offspring trio
and to use the multiple sampled haplotypes when building the
haplotype HMM. When multiple sampled haplotypes are used,
the multiple sampling is accounted for by down-weighting each
haplotype. For example, if k haplotype pairs are sampled for an
unrelated individual, each haplotype is given weight w/k, where
w is the weight per haplotype when only one haplotype pair is
sampled for the individual.
When imputing diallelic markers with alleles A and B in unre-
lated individuals, we calculate posterior genotype probabilities
by summing the probabilities of the HMM states that correspond
to the AA, AB, and BB genotypes. The imputed posterior genotype
probabilities can be used in downstream analyses. We have found
that averaging the posterior genotype probabilities over multiple
iterations of the algorithm increases the imputation accuracy.
When imputing missing ungenotyped markers with a reference
panel, we average posterior genotype probabilities obtained from
iterationsR6.
Our methods for haplotype-phase inference and genotype
imputation are implemented in BEAGLE 3.0. BEAGLE produces
most likely haplotypes and sampled haplotypes for each indi-
vidual with all missing data imputed. When imputing genotypes
in samples of unrelated individuals, BEAGLE produces posterior
genotype probabilities for imputed genotypes. BEAGLE 3.0 also
includes an option for reducing memory usage with a two-level
‘‘checkpoint’’ algorithm.17,18 Checkpoint algorithms store proba-
bilities in HMM calculations for a subset of markers (called check-
points) and then recalculate probabilities from the checkpoints as
needed. Using BEAGLE’s optional checkpoint algorithm increases
running time by a factor of less than two and reduces memory
usage duringHMM sampling fromO(M) to orderO(sqrt[M]), where
M is the number of markers.
All analyses in this study were performed with BEAGLE 3.0 with
default parameter settings (i.e., four samples per individual and
ten iterations). Computing runs were performed on a Linux server
with eight dual-core AMDOpteron 8220 SE processors (running at
2.8 GHz, with a 1 MB cache, and using a 64-bit architecture) and
a total of 64 GB of RAM. All reported computational times were
obtained by adding user and system times from the Linux
‘‘time’’ command, and they thus are equivalent to those that
would be obtained with only a single CPU core.
Real Data Sets
We used unphased trio data fromHapMap release 21 for 30 trios of
Utah residents with ancestry from northern and western Europe
(CEU panel) and 30 trios of Yoruba sampled from Ibadan Nigeriaan Journal of Human Genetics 84, 210–223, February 13, 2009 211
(YRI panel).14 If a marker exhibited a Mendelian inconsistency
in the unphased HapMap data for a trio, the genotypes for that
marker were set to missing in both the parents and the child for
that trio. We assessed the accuracy of our methods for inferring
haplotype phase and missing data in parent-offspring trios by
applying our methods to unphased HapMap CEU and YRI data
and comparing our results with the HapMap’s published phasing
for these data generated with the PHASE program.19 We also
used the HapMap CEU data to compare the accuracy of genotype
imputation with a phased reference panel, an unphased unrelated
reference panel, and an unphased trio reference panel.
We used genotype data from the Affymetrix GeneChip Human
Mapping 500K Array (the Affymetrix 500K chip) generated by the
Wellcome Trust Case Control Consortium (WTCCC).20 The
WTCCC study included approximately 2000 cases for each of
seven diseases (bipolar disorder, coronary artery disease, Crohn’s
disease, hypertension, rheumatoid arthritis, type 1 diabetes, and
type 2 diabetes) and approximately 3000 shared controls. The
shared controls were comprised of 1500 individuals selected
from a UK sample of blood donors and 1500 individuals from
the 1958 British Birth Cohort.21We also used genotype data gener-
ated by the Wellcome Trust Sanger Institute with the Illumina
Inﬁnium HumanHap550 SNP BeadChip (the Illumina 550K
chip) for the 1958 British Birth Cohort samples. Genotypes for
the Affymetrix 500K chip were called with Chiamo,20 and geno-
types for the Illumina 550K chip were called with Illumina’s Gen-
Call software. We excluded all individuals who were excluded by
the WTCCC in their primary analysis.20 For the 1958 British Birth
Cohort, we limited our analyses to 1388 individuals that had been
genotyped on both the Affymetrix and Illumina platforms.
Our previous multilocus analysis of WTCCC data had demon-
strated that multilocus analysis can be particularly sensitive to
intercohort differences in genotype error rates.6 We excluded all
markers that were excluded in the WTCCC’s analysis,20 and we
imposed additional data-quality ﬁlters designed to increase geno-
type accuracy and to excludemarkerswith problematic data. Geno-
types for theAffymetrix500Kchipwere set tomissing if theChiamo
posterior probability for the genotype was <0.99. Genotypes for
the Illumina 550K chip were set to missing if the GenCall score
was <0.6. For members of the 1958 Birth Cohort, genotypes were
set to missing if the Affymetrix and Illumina platforms produced
conﬂicting genotypes. Markers were excluded for a cohort if the
missing ratewas>2% in that cohort or if theHardy-Weinberg equi-
librium p value for themarker was<107.We excluded anymarker
withminor-allele frequency<0.01 in the1958BritishBirthCohort.
Because the interpretation of the genotype depends on the chro-
mosome strand used to deﬁne the alleles, we checked that the
chromosome strandwas consistent between data sets and changed
alleles to their complementary alleles when necessary. Markers
were excluded if the genomic position in NCBI Build 35 coordi-
nates in the marker annotation ﬁles for the Affymetrix data or
for the Illumina data were not consistent with the position given
for themarker in the HapMap data set. A decision to change alleles
to their complementary alleles was based on three sources of infor-
mation: observed alleles (A/C/G/T), minor-allele frequency, and
linkage disequilibrium correlation patterns within a 100 marker
radius. Differences in minor-allele frequency between data sets
were considered signiﬁcant if the difference was >0.2 and if the
difference was signiﬁcant at the 0.01 level. If changing an allele
to the complementary allele for a marker in a data set did not
resolve the discrepancy between data sets, the marker was
excluded from one of the non-HapMap data sets.212 The American Journal of Human Genetics 84, 210–223, FebruarFor chromosome 1, after data-quality ﬁltering, there were
53,683 markers genotyped on the 1958 British Birth cohort with
one or both of the Affymetrix 500K and Illumina 550K chips. A
subset of 24,705 of these markers were present on the Illumina
550K chip and inHapMap phase 2 data14 but absent from the Affy-
metrix 500K chip. This subset of 24,705 markers was masked and
imputed in subsamples of the 1958 British Birth Cohort. From
the 1388 individuals in the 1958 British Birth Cohort, we selected
three random samples of 188, 788, and 1088 individuals. The
24,705 chromosome 1 markers absent from the Affymetrix
500K chip but present on the Illumina 550K chip and in HapMap
phase 2 data were masked in each sample. For each sample, the
remaining 1200, 600, or 300 individuals (or a subset of these
remaining individuals) were used as a reference panel with geno-
type data from both the Affymetrix 500K and Illumina 550K
chip. Althougha proportion of Illumina genotypes for the imputed
markers will be incorrect, this proportion is expected to be small,
and Illumina genotypes are considered to be the true genotype
when computing measures of imputation accuracy in this study.
Comparison with IMPUTE
We compared BEAGLE 3.0 with IMPUTE7 version 0.5.0 in terms
of imputation accuracy and computational efﬁciency. We evalu-
ated imputation accuracy by using Chromosome 1 markers
imputed in a sample of 188 individuals with reference panels of
60 phased individuals (CEU HapMap), 300 unphased individuals,
and 600 unphased individuals. A comparison using larger refer-
ence panels was not practical for the full chromosome 1 data
because of IMPUTE’s much greater computational requirements.
Because IMPUTE requires a phased reference panel, the unphased
reference panels were phased with BEAGLE13 for use in the
IMPUTE analysis. As a result, the accuracy of inferred haplotypes
in the reference panel was similar when imputing genotypes
with BEAGLE or IMPUTE.
We compared the computational efﬁciency of BEAGLE and
IMPUTE for increasingly large reference panels by using a subset
of chromosome1data comprising a5Mb regionwith1356markers
genotyped in the reference sample, ofwhich746markerswere gen-
otyped in the sample. Computational times were measured when
imputing ungenotyped markers in a sample of 188 individuals
with reference panels of 300, 600, and 1200 individuals. For
BEAGLE, the reference samplewas unphased, whereas for IMPUTE,
the reference panel was phased (with phase inferred by BEAGLE).
Simulated Data Sets
We evaluated our trio-phasing methods on large sample sizes with
realistic, simulated trio data. We generated simulated data by using
Cosi22with parameters calibrated to empirical humandata for indi-
viduals with European ancestry (CEU) orwith ancestry of Yoruba in
Ibadan, Nigeria (YRI). Each simulated data set has a recombination
rate sampled fromadistributionmatching theDecodemap.23Three
sample sizes were simulated: 30, 300, and 3000 trios. Four parental
chromosomeswere simulated, andoneof the chromosomesof each
parent was selected to be transmitted to the offspring. The simu-
lated regions were all of 1 Mb in length. For each data set, we
randomly selectedmarkers withminor-allele frequencies of greater
than 0.05 to achieve an averagemarker density of onemarker per 6
kbor onemarker per 1 kb.Onehundred data setswere simulated for
each sample size, ethnicity, and marker density.
In each data set, 0.5% of individual genotypes, chosen at
random, were set to missing. In addition, 0.5% of trios were sety 13, 2009
to missing (i.e., the three genotypes for the trio were all set to
missing, as might be done when a Mendelian inconsistency is
found). These rates of missingness are somewhat different from
those seen in the unphased HapMap Phase II data. In the
HapMap data, after setting trios with Mendelian inconsistencies
to missing, there were 13 single-nucleotide polymorphisms
(SNPs) per Mb per trio with the entire trio missing in the CEU
panel (19 in the YRI panel), compared to 20 in the 1 SNP per kb
simulated data. The rate of sporadic missing data (one or two indi-
viduals in the trio missing at the SNP) was 78 SNPs per Mb per trio
in the CEU panel (83 in the YRI panel), compared to 20 in the
simulated data at the 1 SNP per kb density.
Allelic Association Tests
We investigated the effect of use of imputed genotype data on
power to detect disease associations by comparing p values
computed with true genotype data with p values computed with
imputed posterior genotype probabilities. For this analysis,
p values were computed after excluding 300 individuals in the
1958 British Birth Cohort that were used as an unphased reference
panel. p values were computed for markers that the WTCCC re-
ported as showing evidence of disease association, excluding any
marker that had more than 2% missing data in either of the two
control cohorts or the case cohort. p values were computed three
ways: with genotype data, with imputed data generated from
a phased reference panel of 60 individuals (HapMap CEU), and
with imputed data generated from an unphased reference panel
with 300 individuals. The data for each marker was imputed after
masking that marker in the sample. Standard chi-square, allelic
trend, and Fisher Exact tests are not valid when applied to the
posterior genotype probabilities for imputed data. Hence, we
compared estimated allele dosage in cases and controls with
a two-sample t test. For large sample sizes, the central limit
theorem ensures that the test statistic has the appropriate null
distribution. For genotype data, the allele dosage for each indi-
vidual was obtained from the observed genotype data. For
imputed data, the estimated allele dosage for each individual
was obtained from the imputed posterior genotype probabilities.
For imputed data, p values were computed with only those indi-
viduals who had nonmissing genotype data so that the p values
from imputed data and from observed genotype data are derived
from the same set of individuals.
Metrics for Trio Phasing
We used four metrics to measure accuracy of trio phasing. The
transmission error rate is the proportion of nonmissing parental
genotypes with ambiguous phase that were incorrectly phased.
The denominator of the transmission error rate is the number of
parent genotypes for which the parent is heterozygous and the
transmission is ambiguous (because of missing or heterozygote
genotypes for the child and other parent). The numerator of the
transmission error rate is the number of such parent genotypes
for which the phasing is incorrect (i.e., the incorrect allele is
recorded as having been transmitted). For example, if both parents
and child of a trio have the same heterozygous genotype, the trio
will contribute either 0 or 2 parents to the numerator, and
2 parents to the denominator of the transmission error rate.
The missing trio error rate is the proportion of parental alleles in
trios with missing data for both parent and child that are incor-
rectly imputed. The missing trio error rate has as its denominator
twice (given that there are two alleles per genotype) the number of
parent genotypes for which the parent and child genotypes areThe Americmissing. The numerator of themissing trio error rate is the number
of alleles in such phased parent genotypes that are incorrectly
imputed. For example, if the true phased parental genotype is
AG, and the imputed phased parental genotype is AA, this would
count as one error, whereas if the imputed phased parental geno-
type is GA, this would count as two errors.
The sporadic missing error rate is the proportion of incorrectly
imputed alleles in parents with missing genotype data for them-
selves and nonmissing genotype data for their child. The sporadic
missing error rate has as its denominator twice the number of
parent genotypes for which the parent genotype is missing but
the child genotype is nonmissing. The numerator for the sporadic
missing error rate is the number of alleles in such phased parent
genotypes that are incorrectly imputed (as for the missing trio
error rate).
We also calculated an error rate per trio per SNP, which is the
sum of the numerators of the three types of error (transmission,
missing trio, and sporadic missing error rates), divided by the
number of trios and by the total number of SNPs.
Metrics for Imputation
We assessed the calibration and precision of estimated posterior
genotype probabilities for imputed genotypes. The metrics we
describe below are applied at multiple levels: the genotype level
(genotype concordance rate), the marker level (allelic R2 and stan-
dardized allele frequency), and the study level (allele-frequency
correlation). We also use a Wilcoxon signed-rank test to compare
accuracy of estimated allele frequencies for pairs of imputed data
that were imputed with different reference panels.
Genotype Concordance Rate
The calibration of imputed genotypes was evaluated by calculating
the concordance rate between the most likely imputed genotype
and the true genotype. For imputed genotypes with posterior
probability a, we expect the genotype concordance rate to be
approximately a.
Allelic R2
We assessed the accuracy of imputed genotypes in terms of the
squared correlation between the allele dosage (number of minor
alleles) of the most likely imputed genotype and the allele dosage
of the true genotype. We call this quantity the allelic R2. Allelic R2
has several desirable properties that make it an excellent metric for
evaluating imputation accuracy. Allelic R2 has a simple interpreta-
tion in terms of statistical power, similar to the interpretation of
the squared correlation between two diallelic markers.24 Under
Hardy-Weinberg equilibrium, if an allele confers risk for a disease,
N cases and controls with genotype data for the marker have
approximately the same statistical power to detect association
as N/r2 cases and controls with imputed data for the marker where
r2 is the allelic R2 for the imputed data. Thus, allelic R2 measures
the loss of power when the most likely imputed genotypes are
used in place of the true genotypes for a marker. Association anal-
yses using posterior imputed genotype probabilities can be more
powerful than analysis using most likely imputed genotypes
because posterior genotype probabilities contain more informa-
tion. Consequently, the loss of power measured by allelic R2 is
an upper bound on the loss of power when imputed posterior
genotype probabilities are used in place of the true genotypes for
a marker. Another advantage of allelic R2 is that its interpretation
does not depend on allele frequency.
We show that allelicR2 can be estimated from the imputed poste-
rior genotype probabilities without knowledge of the true geno-
types (see Appendix 1). The ability to estimate allelic R2 froman Journal of Human Genetics 84, 210–223, February 13, 2009 213
imputed posterior genotype probabilities is an important feature
because the true genotype is generally unknown. The estimated
allelic R2 can be used for identifying or excluding markers with
poor imputation accuracy prior to downstream analysis.
Another estimate of imputation accuracy is the ratio of the
variance of the imputed allele dosage and the variance of the
true allele dosage. The variance of the true allele dosage is
unknown, but it can be estimated as 2p(1p) under Hardy-
Weinberg equilibrium, where p is the estimated allele frequency.
This ratio of variances has also been called r2,25 but it does not
directly estimate allelic R2 and thus is different than the allelic
R2 estimate presented in Appendix 1.
Standardized Allele-Frequency Error
For each imputed marker, we deﬁne the allele-frequency error as
the difference between the true allele frequency in the sample and
the estimated allele frequency in the sample computed from the
posterior genotype probabilities. If the three posterior genotype
probabilities for an individual are denoted pAA, pAB, and pBB, then
the estimated A allele frequency is found by summing (2pAA þ pAB)
over all individuals anddividingby twice thenumberof individuals.
However, allele-frequency error is difﬁcult to interpret unless the
true allele frequencyand sample size are known.Anallele-frequency
error of 0.01 is more serious when the allele frequency is 0.01 than
when the allele frequency is 0.5. An allele-frequency error of
0.01 is also more serious when the sample size is 10,000 than
when the sample size is 100 because the larger sample size gives
a much more precise population allele-frequency estimate from
genotype data. Thismotivates us to standardize the allele-frequency
error by the standard error of the population allele-frequency esti-
mate from the true genotype data. If pA is the allele frequency in
the sample of n individuals from a population in Hardy-Weinberg
equilibrium, the standard error of the population allele-frequency
estimate is approximately sqrt(pA[1  pA]/[2n]). If qA is the
estimated allele frequency obtained from the imputed posterior
genotype probabilities, we deﬁne the standardized allele-frequency
error to be
jpA  qA j =ðpA½1 pA=½2nÞ1=2
Thus, a standardized allele-frequency error of z indicates that the
error in estimated allele frequency from imputed data is approxi-
mately z times the standard deviation of the estimated population
allele frequency obtained from the true genotypes.
Allele-Frequency Correlation
The allele-frequency correlation is the correlation over the set of
imputed markers between the estimated sample minor-allele
frequency from imputed posterior genotype probabilities and
the true sampleminor-allele frequency. The allele-frequency corre-
lation can be used for comparing imputation accuracy under
different scenarios, with different reference panels or different
samples.
Wilcoxon Signed-Rank Test
We used a two-sided Wilcoxon signed-rank test to test for differ-
ences in imputation accuracy for markers imputed with two
different reference panels but the same sample. For each imputed
markerm, let Xm be the absolute allele-frequency error using refer-
ence panel 1 and let Ym be the absolute allele-frequency error using
reference panel 2. The null hypothesis of the Wilcoxon signed-
rank test is that the median of Xm  Ym equals 0. Rejecting the
null hypothesis implies that there are differences in accuracy of
the estimated sample allele frequencies derived from the two
reference panels.214 The American Journal of Human Genetics 84, 210–223, FebruarResults
Calibration of Posterior Genotype Probabilities
The posterior genotype probabilities produced by our
methods are well calibrated. Figure 1 presents the genotype
accuracy rate for the imputed genotype with the highest
posterior probability. Genotypes were imputed in a sample
of1088 individualswithaphased referencepanelof60 indi-
viduals, and imputed genotypes were binned according to
their posterior probability. For each bin, the proportion of
imputed genotypes concordant with the called genotype
was approximately equal to the posterior genotype proba-
bility for the bin. Similar results were obtained when impu-
tation was performed with an independent unphased
reference panel of 300 individuals (data not shown).
We also found that our estimate of allelic R2, calculated
from posterior genotype probabilities (see Appendix 1),
hadgoodaccuracy. AllelicR2was estimated for each imputed
marker in a sample of 1088 individuals. Markers were
imputed with a phased reference panel of 60 individuals
(HapMap CEU panel) and imputed with an unphased refer-
encepanelof300 individuals. For thephased referencepanel
(60 individuals), the correlation was 0.938 between the esti-
mated allelic R2 (estimated without knowledge of the true
genotypes) and the actual allelic R2 (calculated from the
true genotypes). For the unphased referencepanel (300 indi-
viduals), the correlation was 0.986 between the estimated
and actual allelic R2. When markers were imputed with the
Figure 1. Calibration of Posterior Genotype Probabilities
Genotypes for chromosome 1 markers on the Illumina 550K chip,
but not the Affymetrix 500K chip, were imputed with a phased
reference panel of 60 individuals (HapMap CEU panel) in a sample
of 1088 individuals genotyped on the Affymetrix 500K chip.
Imputed genotypes are divided into bins according to their poste-
rior genotype probability. The proportion of imputed genotypes
that are consistent with the Illumina genotype are given for
each bin. The line is the set of points with equal posterior genotype
probability and accuracy rate.y 13, 2009
phased reference panel of 60 individuals, 62%, 83%, and
91% of imputed of markers had estimated allelic R2 within
0.05, 0.1, and 0.15, respectively, of the actual allelic R2. For
the larger unphased reference panel of 300 individuals, the
estimates were even more accurate: 87%, 97%, and 99% of
markers had estimated allelic R2 within 0.05, 0.1, and 0.15,
respectively, of the actual allelic R2. We also investigated
the accuracy of the estimated allelic R2 for larger unphased
reference panels and for different sample sizes. As expected,
we found that using larger unphased reference panels
or larger samples increases the accuracy of the estimated
allelic R2 (data not shown).
Effect of Reference Panel Size
We next investigated the effect of reference panel size on
imputation accuracy. Figure 2 shows the cumulative distri-
bution function of allelic R2 in a sample of 188 individuals
for markers imputed with different reference panels:
60 phased individuals (CEU HapMap) and 100, 300, 600,
or 1200 unphased individuals. Figure 2 demonstrates
that increasing the reference panel size markedly increases
imputation accuracy.
Imputation accuracy increases with increased reference
panel size across all frequencies, but the increase is greatest
for the lowest-frequency markers. Figure 3 shows the
median allelic R2 as a function of allele frequency for
imputed markers in a sample of 1088 individuals obtained
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Figure 2. Imputation Accuracy and Reference Panel Sample
Size
Genotypes for markers on the Illumina 550K chip, but not the
Affymetrix 500K chip, were imputed in a sample of 188 individuals
with five different reference panels: 60 phased individuals and 100,
300, 600, and 1200 unphased individuals. For each reference
panel, the proportion of imputed markers whose allelic R2
(see Material and Methods) exceeds each threshold is given. The
allelic R2 for each imputed marker is calculated with the assump-
tion that the Illumina genotypes are the true genotypes.The Americafrom imputation with reference panels of 60 phased
individuals and 300 unphased individuals. The larger,
unphased reference panel has markedly higher median
allelic R2 than the smaller phased reference panel, with
low-frequency markers showing the greatest difference.
With a reference panel of 300 unphased individuals, the
median allelic R2wasR0.92 for all frequency bins. Figure 3
also shows that imputation accuracy tends to increase with
the minor-allele frequency of the imputed marker.
The advantage of larger reference panels is also seen with
the allele-frequency correlation metric. For reference
panels of 60 phased individuals and 100, 300, 600, and
1200 unphased individuals, the allele-frequency correla-
tion increases with reference panel size: 0.9902 (60),
0.9944 (100), 0.9976 (300), 0.9982 (600), and 0.9986
(1200). Similarly, the proportion of imputed markers for
which the standardized allele-frequency error is less than
0.25 also increases: 0.51 (60), 0.60 (100), 0.71 (300), 0.75
(600), and 0.78 (1200).
The advantages of improved imputation accuracy are also
seen when testing imputed markers for association with
a trait. The left panel of Figure 4 shows p values from allelic
association tests (see Material andMethods) usingWTCCC
data for 15 markers that the WTCCC described as showing
the strongest association signals in its study,20 that have
control frequency >0.10, and that have evidence of associ-
ation in replication studies (excludingmarkers in themajor
histocompatibility complex [MHC]). The right panel of
Figure 4 shows p values from allelic association tests for
nine markers showing moderate or strong evidence of
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Figure 3. Median Allelic R2 and Minor-Allele Frequency
Genotypes for markers on the Illumina 550K chip, but not the
Affymetrix 500K chip, were imputed with two different reference
panels in a sample of 1088 individuals genotyped on the Affymetrix
500K chip. For each minor-allele frequency, x¼ 0.01, 0.02,., 0.5,
the median allelic R2 for imputed markers with minor-allele
frequency between x  0.01 and x þ 0.01 is plotted.n Journal of Human Genetics 84, 210–223, February 13, 2009 215
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Figure 4. Allelic Test p values for SNPs
Associated with Disease in the WTCCC
Study
Allelic test p values were computed from
data for approximately 2000 cases and
approximately 2500 controls genotyped
with the Affymetrix 500K chip. Two refer-
ence panels were used for imputing data:
300 unphased individuals genotyped on
both the Affymetric 500K and Illumina
550K chips and 60 phased individuals
from the HapMap CEU panel. For each
marker of interest, p values were calculated
for the original genotype data and for the
imputed data obtained from each reference
panel. The imputed data for each marker of
interest was obtained after masking the
genotype data for the marker in the sample.
The allelic test was a two-sample t test of
the estimated allele dosage in each indi-
vidual. Left panel: p values for 15 markers
(outside the MHC) that have minor-allele
frequency >0.10 in controls, that show the strongest association (p < 5 3 107) on an allelic or genotypic test in the WTCCC study,
and that have evidence of association in replication studies. Right panel: p values for nine markers with minor-allele frequency between
0.06 and 0.10 in controls that were reported to show moderate or strong association (p < 105) on an allelic or genotypic test in the
WTCCC study. One marker (rs6679677) that is associated with two diseases (rheumatoid arthritis and type 1 diabetes) is repeated.association (p < 105) in the WTCCC study, that had
minor-allele frequency<0.10 in controls, and<2%missing
data in each case and control cohort.
The genotype signal data for all markers in Figure 4 were
checked by the WTCCC for conﬁrmation of good geno-
type clustering.20 p values were calculated with genotype
data, with imputed data from a phased reference panel of
60 individuals, and with an unphased reference panel of
300 individuals. In the left panel of Figure 4, there is no
clear difference between the two reference panels for the
15 imputed high-frequency markers, unlike the results in
Figure 2 for the much larger set of imputed chromosome
1 markers. However, for all nine low-frequency markers
in the right panel, p values obtained with a reference panel
of 300 unphased individuals were smaller than p values
obtained with a reference panel of 60 phased individuals.
For six of the nine markers, the p values from the larger
reference panel were at least 25% smaller than the p values
from the smaller reference panel. All of these markers had
minor-allele frequencies >0.06 (but <0.10) in controls.
Figure 3 suggests that larger reference panels will have
even greater impact on p values for markers with minor-
allele frequency <0.06.
For somemarkers in Figure 4, the p value calculated from
imputed data is smaller than the p value calculated from
genotypedata. This could indicate thepresenceof genotype
error in the original data. However, genotype error rates
should be extremely low because of our stringent data-
quality ﬁlters, and the WTCCC reported good genotype
clustering for all of these markers.20 In our view, a more
likely explanation for the occasional smaller p value from216 The American Journal of Human Genetics 84, 210–223, Februarimputed data is the variability in the estimates of allele
dosage from imputed data.
Comparison with IMPUTE
We measured imputation accuracy for BEAGLE 3.0 and
IMPUTE 0.5.0 with reference panels of 60, 300, and 600
individuals and a sample of 188 individuals. The difference
in accuracy between BEAGLE and IMPUTE decreases as the
size of the reference panel increases. The allele-frequency
correlations were 0.9902 (BEAGLE) and 0.9917 (IMPUTE)
with a reference panel of 60 individuals, 0.99753 (BEAGLE)
and 0.99761 (IMPUTE) with a reference panel of 300 indi-
viduals, and 0.99824 (BEAGLE) and 0.99822 (IMPUTE)
with a reference panel of 600 individuals. The difference
in accuracy between IMPUTE and BEAGLE is substantially
smaller than the gain in accuracy obtained from using
larger reference panels.
We also compared computation times for BEAGLE and
IMPUTE when imputing data in a 5 Mb region of chromo-
some 1 in a sample of 188 individuals with reference panels
of 300, 600, and 1200 individuals. Running times for
BEAGLE were 2.7 min, 5.5 min, and 12.0 min for reference
samples of 300, 600, and 1200 unphased individuals.
Running times for IMPUTE were 60.3 min, 220.2 min, and
829.6 min for reference samples of 300, 600, and 1200
phased individuals. IMPUTE’s computation times increased
relative toBEAGLE’s as the referencepanel size increases, and
for a reference panel of 1200 individuals, IMPUTE’s compu-
tation time was 69 times longer than BEAGLE’s. IMPUTE
required 33 Gb of memory to impute data for the 5 Mb
region when using a reference panel of 1200 individuals,y 13, 2009
and BEAGLE required 1 Gb. IMPUTE could be modiﬁed to
reduce memory usage by using a checkpoint algorithm
(see Material and Methods), but this modiﬁcation would
be expected to double IMPUTE’s running time.
Computational times for IMPUTE are approximately
quadratic in the size of the reference panel and linear in
the size of the sample. Computational times for BEAGLE
depend on the combined size of the reference panel and
the sample. BEAGLE’s computation time can be made
linear in the size of the sample by dividing the sample
into disjoint subsamples and performing imputation sepa-
rately in each subsample.
Other Factors Affecting Imputation Accuracy
Size of the Sample
The accuracy of estimated allele frequency increases as the
size of the sample increases. However, the effect of the
sample size on imputation accuracy is much smaller than
theeffect of the referencepanel sizeon imputationaccuracy.
Genotypes were imputed in samples of 1088, 544 (1088/2),
and 272 (1088/4) individuals. As the sample size increases,
the allele-frequency correlation increases, as follows:
0.9981 (272), 0.9985 (544), and 0.9987 (1088). Although
the allele-frequency correlation increases with sample size,
the proportion of markers with standardized allele-
frequency error<0.25decreases as the sample size increases,
as follows: 0.69 (272), 0.64 (544), 0.56 (1088). Thus, as the
sample size increases, a larger portion of the error in the
population allele-frequency estimate is due to imputation,
and a smaller proportion of the error is due to sampling
variability in the sample. Similar results were seen with
a reference panel of 60 phased individuals (HapMap CEU)
and samples of 272, 544, and 1088 individuals.
Population Differences between Sample and Reference Panel
Figure 2 shows that imputation using a reference panel of
60 phased individuals is less accurate than imputation
using a reference panel of 100 unphased individuals.
Some of this difference in accuracy may be due to popula-
tion differences between the sample and the reference
panel. The reference panel of 60 phased individuals is
from the HapMap CEU data, whereas the reference panel
of 100 unphased individuals and the sample are both
from the 1958 British Birth Cohort. We investigated the
effect of these population differences while controlling for
differences in markers, haplotype phasing, and reference
panel size. We did not control for differences in sporadic
missing data and genotype error proﬁles that exist between
the HapMap CEU data and the 1958 British Birth Cohort
data. However, we expect differences in missing genotype
proﬁles and genotype error proﬁles to have a relatively
minor effect on imputation accuracy because of the strin-
gent quality-control ﬁltering we applied to the 1958 British
BirthCohort data and the high quality of theHapMap data.
We compared two unphased reference panels of 60 indi-
viduals each. One unphased reference panel was the
parental data for the 30 CEU HapMap trios obtained by
randomly phasing the phased parental data. The otherThe Americunphased reference panel was 60 individuals from the
1958 British Birth Cohort. Both reference panels were
restricted to the markers genotyped on at least one of the
Affymetrix or Illumina chips. We used each unphased
reference panel to impute markers in the sample of 188
individuals from the 1958 British Birth Cohort. The
allele-frequency correlation was 0.9895 with the unphased
HapMap CEU reference panel and 0.9903 with the 1958
British Birth Cohort reference panel. For comparison, the
allele-frequency correlation with a larger unphased refer-
ence panel of 100 individuals from the 1958 British Birth
Cohort was 0.9944. This indicates that most of the differ-
ence in imputation accuracy seen in Figure 2 between
the reference panel of 60 phased individuals (HapMap
CEU) and the reference panel of 100 unphased individuals
is due to sample size rather than to population differences
between the HapMap reference panel and the sample.
Phased versus Unphased Reference Panel
Because the phase of unphased data can be inferred, we
expect any difference in imputation accuracy between
phasedandunphased referencepanelswill reﬂect thediffer-
ence in haplotype-phase accuracy between phasing unre-
lated individuals and parent-offspring trios. We imputed
Illuminamarkers in 1088 individuals with phased parental
data (phased with PHASE19) for the 30 Hapmap CEU trios
and with unphased parental data for the 30 HapMap
CEU trios. The unphased parental data was obtained by
randomly ordering the heterozygote genotypes in the
phased parental data. The difference in imputation accu-
racy was small but statistically signiﬁcant (Wilcoxon test
p < 108). The allele-frequency correlation was 0.9908
with unphased parental data and 0.9916 with phased data.
Trio Reference Panel
All applications of imputation to genome-wide association
studies that we have seen so far have used phased HapMap
data as a reference panel. The inferred haplotypes in the
phased HapMap data are extremely accurate because they
are obtained from parent-offspring trio data.15 However,
one disadvantage of using a phased reference panel is
that any uncertainty in the inferred haplotype phase and
missing data imputation is ignored. This disadvantage
can be overcome by using unphased trio data as a reference
panel. We performed imputation in a sample of 1088 indi-
viduals with unphased HapMap CEU trio data as a refer-
ence panel and compared the imputation accuracy to
results obtained with the corresponding phased HapMap
data. As expected, imputation using a trio reference panel
was slightly more accurate than imputation using a phased
reference panel. The difference in imputation accuracy was
small but statistically signiﬁcant (Wilcoxon test p < 107).
The allele-frequency correlation was 0.9916 with phased
parental data and 0.9918 with trio data.
Model Averaging
Oneway of obtaining an additional small increase in impu-
tation accuracy is to perform imputation multiple times
and average the resulting posterior probabilities. We used
a reference panel of 30 parent-offspring trios and a samplean Journal of Human Genetics 84, 210–223, February 13, 2009 217
Table 1. Error Rates for Phasing Trios
Data Source
Number
of Trios SNPs/kb Ethnicity
Transmission
Error Rate
Missing Trio
Error Rate
Sporadic Missing
Error Rate
Errors per
Trio per SNP
Simulated with Cosi 3000 6 CEU 0.0047 0.0080 0.0042 0.00083
Simulated with Cosi 3000 6 YRI 0.0017 0.0058 0.0031 0.00035
Simulated with Cosi 300 6 CEU 0.0095 0.0130 0.0069 0.00154
Simulated with Cosi 300 6 YRI 0.0116 0.0198 0.0108 0.00179
Simulated with Cosi 30 6 CEU 0.0224 0.0237 0.0125 0.00341
Simulated with Cosi 30 6 YRI 0.0321 0.0420 0.0231 0.00447
Simulated with Cosi 3000 1 CEU 0.0006 0.0009 0.0005 0.00010
Simulated with Cosi 3000 1 YRI 0.0003 0.0009 0.0005 0.00006
Simulated with Cosi 300 1 CEU 0.0018 0.0029 0.0015 0.00030
Simulated with Cosi 300 1 YRI 0.0012 0.0028 0.0014 0.00020
Simulated with Cosi 30 1 CEU 0.0061 0.0095 0.0050 0.00102
Simulated with Cosi 30 1 YRI 0.0045 0.0098 0.0051 0.00074
HapMap phase II 30 ~1 CEU 0.0388 0.0351 0.0143 0.00456
HapMap phase II 30 ~1 YRI 0.0188 0.0465 0.0185 0.00357
Definitions of the error rates are given in the Material and Methods section.of 188 individuals. We imputed data four times and used
a different seed for generating random numbers in each
run. The allele-frequency correlation for the markers on
the Illumina chip was 0.9904 for the ﬁrst run, 0.9909 for
the average posterior probabilities from the ﬁrst two runs,
and 0.9911 for the average posterior probabilities for all
four runs. The difference in imputation accuracy was statis-
tically signiﬁcant when comparing results from different
numbers of runs (Wilcoxon test p < 1015).
Dividing the Sample
We investigated the imputation accuracy and computa-
tional efﬁciency when dividing a sample into subsets and
imputing data in each set separately. Imputation was per-
formed on the entire sample of 1088 individuals and also
on four equal-sized subsamples of 272 individuals. For
a reference panel of 60 phased individuals and a sample of
1088 individuals, the allele-frequency correlation was
0.9916 for the entire sample and 0.9923 for the subdivided
sample. For a reference panel of 300 unphased individuals,
the allele-frequency correlation was 0.9987 for the entire
sample and 0.9988 for the subdivided sample. The increase
in allele-frequency correlation with the subdivided sample
is probably due to the beneﬁts of model averaging, given
that the allele-frequency estimates for each subsample are
obtained from a different random model. Total computa-
tional time for imputing genotypes on the four subsamples
was less than the computational time for imputing geno-
types on the entire sample. Dividing a sample into subsets
and imputing data in each subset separately can decrease
total computing time because computing time for our
methods scales more than linearly in the size of the
combined reference panel and sample. Dividing a sample
into subsets also permits imputation in each subset to run
in parallel to further reduce the effective computing time.
Trio Phasing
Table 1 shows error rates for phasing trios. Error rates
decrease with increasing sample size and with increasing218 The American Journal of Human Genetics 84, 210–223, FebruarSNP density. There is no clear pattern of difference
between CEU and YRI data—for some combinations of
marker density and sample size, CEU has lower error rates,
whereas for others, YRI has lower error rates. The real data
(HapMap Phase 2) has an approximately ﬁve times higher
error rate than the corresponding simulated data (30 trios
at a density of 1 SNP per kb). A possible explanation for
this is that for the simulated data, the true genotypes
and phase with which imputed genotypes and phase are
compared are known without error, whereas for the real
HapMap data, there are two signiﬁcant sources of error.
First, there are probably some genotype errors in the
HapMap data, so that the imputed genotype and phase
may be correct but look incorrect. Second, we do not
know the true genotype and phase, but we are comparing
our results to those obtained by PHASE (i.e., the HapMap
phased data). Thus, whenever our imputation differs
from that of PHASE, we record it as an error; however,
we have no way to know whether the error is from our
method or from PHASE.
Overall, the error rates in imputed genotypes and phase
in trios are extremely low. The error rate per trio per SNP in
Table 1 ranges from 0.4% to 0.006%. The transmission
error rate (incorrect determination of transmitted allele
from a heterozygous parent, where the other parent and
the child are heterozygous or missing) in Table 1 ranges
from 4% to 0.03%. Thus, although we have not directly
compared our trio-phasing results to those from the most
accurate competing methods (which was not possible
because of the high computing requirements or inability
to analyze large data sets of existing software implement-
ing those methods), the error rates are so low that any
such comparison would have little practical value.
We attempted to use PHASE v2.1.1 to phase one of our
smaller simulated data sets (300 trioswith 167 SNPs in simu-
lated YRI). In order to do, we ﬁrst had to split the data into
two components of 83 and 84 markers. The total time for
the analysis was 56 hr. In comparison, BEAGLE analyzedy 13, 2009
these data (without splitting into two components) in 14 s.
Our software took a total of 5.5 hr to phase the 3.8 million
autosomal markers for the 30 HapMap Phase II CEU trios
and 6.3 hr for the 3.7 million autosomal markers for the
30 YRI trios. Phasing times for 3000 simulated trios on
1000markers (1 SNPperkb)werehighlyvariable, depending
on the extent of linkage disequilibrium and missing data
patterns, and had a mean time of 122 min.
Discussion
New Methods
The newmethods presented here for genotype imputation
and haplotype phasing provide a uniﬁed approach to the
problem of missing data and haplotype-phase inference.
Our methods permit family data (parent-offspring pairs or
trios) to be analyzed simultaneously with phase-unknown
and phase-known genotype data from unrelated individ-
uals, with missing genotypes being automatically imputed
during haplotype phasing.We show that ourmethods scale
easily to permit analyses of thousands of individuals. This
ﬂexibility and capability is expected to be particularly valu-
able as new, larger reference panels become available (e.g.,
HapMap phase 3 data). We have demonstrated that our
imputation and haplotype-phasing methods achieve
a high level of accuracy and that the posterior probabilities
produced by our methods are well calibrated.
We also presented a newmethod for estimating allelic R2,
the correlation between the imputed and true allele dosage
for a marker. We showed empirically and theoretically that
allelic R2 can be accurately estimated when the imputed
posterior probabilities are accurately calibrated (as they
are for our method). Allelic R2 is a natural metric for
estimating imputation accuracy that is normalized for
marker-allele frequency. The estimated allelic R2 can be
used for estimating the loss in statistical power when using
imputed data in place of genotype data for a marker. The
allelic R2 metric can also be used for detecting intercohort
differences in imputation accuracy that could bias statis-
tical tests for association in amanner similar to ‘‘differential
missingness.’’26
Importance of Large Reference Panels
One important conclusion from this study is that the size of
the reference panel has a substantial impact on imputation
accuracy, particularly when imputing low-frequency
genetic variants. We have demonstrated with WTCCC
data that the use of large reference panels produces substan-
tial gains in imputation accuracy and that improved impu-
tation accuracy results in lower p values when testing
low-frequency disease-associated variants.
With our methods, it is relatively unimportant whether
the reference panel is phased or unphased because the
phase of genotype data for unrelated individuals can be
inferred during genotype imputation with good accuracy.
We have shown that a reference panel of 100 unphased
individuals gives markedly more accurate imputed geno-The Americtypes than a reference panel of 60 phased individuals.
This is not surprising because unphased genotype data
contain almost as much information as phased genotype
data. This is why samples of unrelated individuals with
unphased genotype data can be phased with fairly high
accuracy.
The value of a large reference panel is most evident when
imputing low-frequency genetic variants. We have shown
that variants with frequency as low as 1% are accurately
imputed (with high allelic R2) when using a large reference
panel. We expect that large reference panels can be used
for accurately imputing markers with frequency <1%
provided that the reference panel and sample genotype
data are sufﬁciently accurate.
The results from this study are consistent with previous
work showing that the BEAGLE haplotype HMM gives
good results for small sample sizes and excellent results for
large sample sizes.13 In our earlier work applying the
BEAGLE model to haplotype-phase inference in unrelated
individuals, there was no reference panel as such, and this
result applied to thewhole sample.Here, in thecaseof impu-
tation, the critical quantity is the size of the reference panel.
We have compared our imputation method with
IMPUTE, one of the best-performing and widely used
imputation methods. We have shown that IMPUTE is
slightly more accurate than BEAGLE for small reference
panels, but much bigger gains in imputation accuracy are
obtained by using larger reference panels. We also show
that BEAGLE scales easily to the larger reference panel
sizes, whereas IMPUTE does not. One could modify
IMPUTE to reduce its computational time by constraining
the complexity of its HMM (e.g., by limiting the number
of HMM states). However, constraining the model
complexity would be expected to reduce imputation accu-
racy because more complex models are needed to use the
full information in larger reference panels. Other excel-
lent, state-of-the-art methods that use HMMs similar to
those used by IMPUTE face similar challenges with large
reference panels (Li et al., 2007, Am. Soc. Hum. Genet.,
abstract 2071).1,27 In contrast, BEAGLE can model large-
scale data sets with 15,000 or more individuals without
constraining the complexity of its haplotype frequency
model.6 This enables BEAGLE to achieve increased imputa-
tion accuracy by making full use of the data in large
reference panels.
New Analysis Options
Our methods provide researchers with additional options
for imputing genotypes. In the current study, we have
used reference panels genotyped on the Affymetrix
500K and Illumina 550K chips. However, much denser
genotyping chips are now available. The Affymetrix
Genome-wide Human SNP Array 6.0 has 900K SNPs,
and the Illumina Human 1M Beadchip has over 1M
SNPs. Our work indicates that the accuracy of genotype
imputation in the British population could be improved
by genotyping the 1958 British Birth cohort on thean Journal of Human Genetics 84, 210–223, February 13, 2009 219
densest genotype chips available and using this cohort as
an unphased reference panel.
When a reference panel for a population is not available,
one can still choose a subset of the sample to genotype
with a larger set of markers (e.g., the Affymetrix 6.0 chip
or the Illumina 1M chip) and use the densely genotyped
subset to impute the SNPs for the remainder of the
sample.28 An additional advantage of this approach is
that the reference panel is perfectlymatched to the sample.
One of the most valuable uses of genotype imputation
has been combining data from multiple studies that have
used different genotyping platforms, thus increasing
power to detect associations.3,5 For European cohorts, our
results indicate that use of a large reference panel, such
as the 1958 British Birth Cohort, that has been genotyped
on both Affymetrix and Illumina genotype platforms will
substantially increase power compared to use of smaller
reference panels, such as the HapMap phase 2 CEU panel.
With our methods, one can also use trio data directly for
imputation. Using trios as a reference panel permits any
phase uncertainty in the trio data to be accounted for
when imputing genotypes. Our trio-phasing methods
also make it easy to impute variants that are not included
in the phased HapMap. For example, current genotype
arrays contain SNPs that are not present in the phased
HapMap CEU and YRI data. Because HapMap panels are
typically genotyped with these commercial arrays, the
resulting genotypes can be added to HapMap data and
used as a trio reference panel. Also, data for HapMap phase
3 samples have been genotyped on the Affymetrix 6.0 and
Illumina 1M platforms. These data are publicly available
from the HapMap web site, and population cohorts from
these data can be used as reference panels in BEAGLE for
genotype imputation.
Software Implementation
Our imputation and haplotype-inference methods are
implemented in version 3.0 of the BEAGLE software
package, which is freely available. BEAGLE 3.0 enables users
to combinemultiple data sets in a single analysis to increase
sample size and accuracy. In particular, users can simulta-
neously analyze phased and unphased data for unrelated
individuals and parent-offspring pairs and trios. BEAGLE is
written in Java and runs on all major computing platforms.
Appendix 1: Estimating Allelic R2
We have used the squared correlation between the
imputedmost likely allele dosage and the true allele dosage
for a marker (allelic R2) to measure the accuracy of geno-
type imputation for the marker. This squared correlation
is an attractive measure because it has a simple interpreta-
tion in terms of sample size and power24 and because its
interpretation does not depend on the marker-allele
frequency. In this appendix, we show that the correlation
between the imputed and true allele dosage can be esti-
mated from the posterior genotype probabilities when220 The American Journal of Human Genetics 84, 210–223, Februarthe true genotypes are not observed. The results in this
study show that the estimate of allelic R2 has good accuracy
when the posterior genotype probabilities are accurately
calibrated and informative.
We use the following random variables: X ¼ the unob-
served true genotype, Y ¼ the imputed posterior genotype
probabilities, and Z ¼ the genotype with highest posterior
probability (based on Y).
The values of the random variables X and Z can take
values of 0, 1, or 2, corresponding to the number of copies
(dosage) of the minor allele in the genotype. The random
variable Y is a vector-valued random variable whose values
are ordered triplets (a0, a1, a2) where ak is the posterior
genotype probability of genotype k (k ¼ 0, 1, or 2). Assume
there are n individuals in the sample. Let yi be the ordered
triplet of posterior genotype probabilities in the i-th
sample, let yi(k) denote the posterior probability of geno-
type k in the i-th sample, and let zi be the most likely
imputed genotype in the i-th sample. We assume that
the posterior probabilities are accurately calibrated, so
that the probability P(X ¼ k j Y ¼ yi) ¼ yi(k).
The squared correlation (R2) between the unobserved
true allele dosage and the imputed allele dosage is equal to
R2 ¼ CovðX,ZÞ2=ðVarðXÞ VarðZÞÞ (1)
where Cov(X, Z) is the covariance of X and Z, and Var(X)
and Var(Z) are the variances of X and Z, respectively. We
can estimate R2 by expressing Cov(X, Z), Var(X), and
Var(Z) in terms of the imputed data zi and yi.
We estimate the variance of Z and X by using the sample
mean:
VarðZÞ ¼ EZ2 ðE½ZÞ2
zð1=nÞSiz2i 

1=n2
 ðSiziÞ2
VarðXÞ ¼ EX2 ðE½XÞ2
¼ EEX2 jY ðE½E½X jYÞ2
zð1=nÞSiE

X2 j yi
 1=n2 Si E½X j yi
2
Similarly, we use the sample mean to estimate covariance
of X and Z as
CovðX,ZÞ ¼ E½XZ  E½X E½Z
¼ E½E½XZ jY  E½E½X jY E½Z
zð1=nÞSi

zi E

X j yi
 1=n2 Si E

X j yi

Si zi
An estimate for allelic R2 is obtained by substituting the
values of E[X j yi] and E[X2 j yi] into the estimates for
Cov(X, Z) and Var(X) and using Equation 1. Let ui ¼
E[X j yi ] ¼ yi(1) þ 2yi(2) and wi ¼ E[X2 j yi ] ¼ yi(1) þ 4yi(2);
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R2z½Si zi ui  ð1=nÞ ðSi ui Si ziÞ2=
ð½Si wi  ð1=nÞ ðSi uiÞ2½Si z2i  ð1=nÞ ðSi ziÞ2Þ
Appendix 2: Haplotype Hidden Markov Models
Using Rabiner’s notation,16 the ﬁve components of a HMM
are as follows: (1) hidden states: S1, S2, . SN; (2) observed
values: v1, v2, ., vM; (3) state-transition probabilities:
aij is the probability of a state transition from state Si to
state Sj; (4) emission probabilities: bj(vk) is the probability
of observing value vk in state Sj; and (5) initial-state proba-
bilities: pi is the probability that the HMM process starts
in state Si.
We assume that there are Dmarkers ordered in chromo-
somal order. For simplicity, we assume that all markers are
diallelic, but the model generalizes to the multiallelic case.
Our methods are applicable to any HMM that meets the
following two conditions. First, the HMM is leveled with
D levels (one level per marker). In a leveled HMM, each
state belongs to a single level, the ﬁrst level consisting of
states with nonzero initial probabilities, and all state tran-
sitions with nonzero probability are from states at level l to
states at level l þ 1. Second, the set of observed values
consists of all alleles for all markers, and the only values
emitted with nonzero probability by states at level l are
alleles for the l-th marker.
We will call a HMM that satisﬁes the preceding condi-
tion a haplotype HMM. The class of haplotype HMMs is
very broad and includes the models used by many state-
of-the-art programs for inferring haplotype phase and
missing data (Li et al., 2007, Am. Soc. Hum. Genet.,
abstract 2071).7,13,27 Haplotypes, with or without missing
alleles, can be considered as sequences of emitted values
from the haplotype HMM. We assume that the observed
data is consistent with the haplotype HMM, so that stan-
dard HMMmethods can be used for determining the prob-
ability of each sequence of hidden states that is consistent
with the observed data. In particular, we can sample
a sequence of states from the haplotype HMM, and we
can determine a probability distribution for the missing
data conditional on the observed allele data with standard
HMM methods.13,16
A haplotype HMM, H, determines HMMs for genotype
data from unrelated individuals, parent-offspring pairs,
and parent-offspring trios. For unrelated individuals,
phased genotype data is a pair of haplotypes. Thus, for an
individual, we use a HMM denoted H2, whose states are
ordered pairs of states from each level of H. For a parent
and offspring where one parent is ungenotyped, we use
a HMM H3, whose states are ordered triplets of states from
each level ofH. Theordered triplets represent thegenotyped
parent’s transmitted allele, the genotyped parent’s untrans-
mitted allele, and the child’s allele received from the ungen-
otypedparent. Forparent-offspring triodata,weuse aHMM
H4whose states areorderedquartets of states fromeach level
ofH. The ordered quartet represents the ﬁrst parent’s trans-The Americmitted and untransmitted alleles and the second parent’s
transmitted and untransmitted alleles.
The formal deﬁnition of the HMM, Hk for k ¼ 1, 2, 3,.,
is as follows. Let Ll be the set of states in H at level l. The
states of the HMM Hk are the union over l of all ordered
k-tuples of states in Ll. The transition probability between
two states ofHk is equal to the product of the element tran-
sition probabilities in H. For example, the transition prob-
ability from state (S1, S2, S3) to state (S4, S5, S6) inH
3 is equal
to a13a24a36. The initial probability of a state s in H
k is the
product of the initial probabilities of the elements of s. For
example, the initial probability of state (S1, S2, S3) is p1p2p3.
The observed values inHk are fk(v*) where v* is an ordered
k-tupleof emittedvaluesofH, and fkare functions,described
below, that transform ordered k-tuples of values of H into
observed genotype data. The functions fk are not one to
one because genotypes are unordered pairs and k-tuples
are ordered. So calculations of emission probabilities
must sum over the inverse image fk
1(fk(v*)) consisting of
all k-tuples of values in H that are mapped to fk(v*). For
each element of the inverse image, the probability of
observing the corresponding emission probability is the
product of the component emission probabilities in H. For
example, if f3
1(f3(v1, v2, v3)) contains two elements, (v1, v2,
v3) and (v4, v5, v6), the probability of observing f3(v1, v2, v3)
in state (S7, S8, S9) is b7(v1)b8(v2)b9(v3) þ b7(v4)b8(v5)b9(v6).
With these deﬁnitions, Hk is a leveled HMM.
Given a haplotype HMM H, we use H2, H3, H4 to infer
phase and missing data in diploid individuals, parent-
offspring pairs, and parent-offspring trios, respectively.
The functions fk transform ordered k-tuples of values of
H into genotypes. For individuals, f2 maps the ordered
pair of values (v1, v2) to the corresponding unordered geno-
type. For parent-offspring data, f3 maps the ordered triplet
of values (v1, v2, v3) to parent genotype f2(v1, v2) and to
child genotype f2(v1, v3). For parent-offspring trio data,
f4 maps the ordered quartet of values (v1, v2, v3, v4) to
ﬁrst-parent genotype f2(v1, v2), to second parent genotype
f2(v3, v4), and to child genotype f2(v1, v3).
Given a haplotype HMM and diploid data for a set of
individuals, parent-offspring pairs, or parent-offspring
trios, with or without missing data, one can use standard
HMM methods to sample a sequence of hidden states
(ordered k-tuples) conditional on the observed data or to
determine a probability distribution for missing data.
Sampled hidden states can be used for determining a
haplotype phasing consistent with the observed genotype
data.
Appendix 3: The BEAGLE Haplotype HMM
Appendix 2 details the general haplotype HMM frame-
work. Here, we describe the particular haplotype HMM
that we use in our method. The model is most easily
described by detailing the procedure from which it is built
with haplotype data.an Journal of Human Genetics 84, 210–223, February 13, 2009 221
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,A BModel-building steps Figure 5. Building the BEAGLE HMM
(A) Building level lþ1 from level l. The first
step is merging. In this example, states S1
S2, and S4 are merged, and states S3 and S5
are merged. After merging, haplotype clus-
ters are split on the basis of the allele at
marker lþ1. All haplotypes in states S7
and S10 have allele 1 at this marker
whereas all haplotypes in states S8, S9
and S11 have allele 2.
(B) Transition probabilities between the
states at the two levels. All transitions
with nonzero probabilities are shown. Tran-
sitions with the same probability have the
same pattern on the arrow shaft.The model-building process proceeds along a chromo-
some frommarker to marker. Each step involves ‘‘merging’’
and ‘‘splitting’’ of haplotype clusters, which are the states of
the HMM. At the ﬁrst level (corresponding to the ﬁrst
marker) of the haplotype HMM, the haplotypes are clus-
tered according to the allele at the ﬁrst marker. Thus for
a SNP marker, there will be two clusters (i.e., two states),
one containing all haplotypes for which the ﬁrst allele is
the major allele, and the other containing all haplotypes
for which the ﬁrst allele is theminor allele. In creating level
lþ1 from level l, a merging and a splitting step are applied.
The merging step involves calculating a merging score
(described below) for each pair of haplotype clusters. If
the smallest score is less than the threshold (given below),
the corresponding pair of haplotype clusters will bemerged
into a single cluster, and the merging step is repeated with
the new set of haplotype clusters. Once all merging has
been completed, eachhaplotype cluster is split by the alleles
at marker lþ1. Again, for a SNP marker, all haplotypes in
a cluster carrying the major allele at marker lþ1 will form
one new cluster, whereas all haplotypes in the cluster
carrying the minor allele at marker lþ1 will form another
cluster. The new clusters obtained at the end of the splitting
procedure are the states of the haplotypeHMMat level lþ1.
Figure 5A illustrates the process.
Themerging score for two clusters at level l is obtained as
follows. Inmerging two clusters, we askwhether their prob-
abilities of allele sequences at markers lþ1, lþ2, . differ.
The score is the maximum over k (k ¼ 1, 2,.) and over all
possible sequences of alleles at markers lþ1, lþ2,., lþk of
the observed frequencydifference of this sequence between
the two clusters. The observed frequency accounts for any
weighting of individuals. For example, if cluster one
contains ﬁve fully weighted individuals, of whom three
have the sequence ACG atmarkers lþ1, lþ2, lþ3, plus three
individuals weighted at 0.1, of whom one has this
sequence, the observed frequency for this sequence in this
cluster is 3.1/5.3. A worked example for the case in which
all individuals have unit weight is given in our earlier
work.29 The threshold on the scores is sqrt(1/nx þ 1/ny),222 The American Journal of Human Genetics 84, 210–223, Februarwhere nx and ny are the sum of the weights of each cluster
(e.g., 5.3 for the cluster described above). A rationale for
this threshold is given in our earlier work.29
All haplotypes within a cluster at level l have the same
allele at marker l because of the splitting process (see
Figure 5A). Thus, the emission probabilities are all 0/1. The
transition probabilities can be obtained from the cluster
counts. The transition probability from state SA at level l to
state SB at level lþ1 is the number of haplotypes in SBdivided
by the sum of haplotype counts from all parent states of SB.
Because state SB is derived by merging and then splitting
states at the previous level, the parent states of SB are all
the states at level l that contribute to the merged cluster
fromwhich state SBwas derived (by splitting). For, example,
inFigure5B, state S7 at level lþ1hasn1haplotypes, and states
S1, S2, and S4, the parent states, have n1 þ n2 haplotypes
among them. Thus, the transition probability from S1 to S7
is n1/(n1 þ n2) (which is also the transition probability
fromS2 toS7or fromS4 toS7).Asbefore, thehaplotypecounts
areweighted counts if some individuals are down-weighted.
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